Physician profile
Debbie Preble
NPI 1124165170
$8,473.79
in general payments reported to CMS, 2019-2025
44 companies · $2,695 in 2025
The $2,695 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $894 · 2022: $1,353 · 2023: $1,824 · 2024: $1,707 · 2025: $2,695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,079 · Travel and Lodging: $1,127 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,079.35 |
| Travel and Lodging | $1,127.01 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,391.66 | 2021-2025 | Minimed 780g |
| Astrazeneca Pharmaceuticals Lp | $797.61 | 2021-2025 | Farxiga |
| Novo Nordisk INC | $746.09 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $496.31 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Lilly USA, LLC | $448.78 | 2021-2025 | Mounjaro, Jardiance, Baqsimi |
| Amgen INC. | $442.12 | 2022-2025 | Evenity, Tepezza, Prolia |
| Abbvie INC. | $340.75 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $330.69 | 2021-2025 | |
| Dexcom, INC. | $281.91 | 2021-2024 | Dexcom G6 Transmitter |
| Ibsa Pharma INC. | $257.54 | 2022-2025 | Licart, Tirosint, Flector |
| Abbott Laboratories | $205.66 | 2021-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $174.20 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $166.35 | 2022-2024 | Recorlev, Gvoke Hypopen |
| Mannkind Corporation | $139.35 | 2021-2024 | Afrezza |
| Tandem Diabetes Care, INC. | $130.38 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $109.18 | 2022-2024 | Korlym |
| Kyowa Kirin, INC. | $75.31 | 2023-2024 | Crysvita |
| Insulet Corporation | $75.02 | 2022-2025 | Omnipod |
| Acella Pharmaceuticals, LLC | $71.30 | 2022-2024 | NP Thyroid 60 |
| Alexion Pharmaceuticals, INC. | $68.21 | 2022-2024 | Strensiq |
| Radius Health, INC. | $63.06 | 2023-2025 | |
| Amarin Pharma, INC. | $53.79 | 2021-2023 | |
| Ascensia Diabetes Care US INC. | $51.45 | 2022-2024 | |
| Cequr Corporation | $47.22 | 2021-2023 | Cequr Simplicity |
| Beta Bionics, INC. | $41.22 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Antares Pharma, INC. | $40.94 | 2024 | Xyosted |
| Vivus LLC | $40.21 | 2023-2024 | Pancreaze, Qsymia |
| Amphastar Pharmaceuticals, INC. | $39.32 | 2024-2025 | |
| Tolmar, INC. | $33.77 | 2024-2025 | Jatenzo |
| Becton, Dickinson and Company | $33.36 | 2021-2022 | |
| Nevro Corp. | $33.25 | 2022 | |
| Embecta Corp. | $26.51 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Novartis Pharmaceuticals Corporation | $24.85 | 2022 | |
| Zealand Pharma US, INC. | $21.61 | 2021 | |
| Merck Sharp & Dohme LLC | $21.24 | 2023 | Segluromet, Steglatro, Steglujan |
| Bigfoot Biomedical INC | $20.01 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.42 | 2022 | |
| Currax Pharmaceuticals LLC | $17.95 | 2022 | |
| Clarus Therapeutics INC. | $17.26 | 2021 | |
| Intuity Medical INC | $17.14 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Glaxosmithkline, LLC. | $16.68 | 2023 | Shingrix |
| Recordati_rare_diseases_inc. | $15.81 | 2024 | Signifor Lar, Isturisa |
| Lifescan, INC. | $15.27 | 2021 | |
| Esperion Therapeutics, INC. | $15.03 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debbie Preble listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.